H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $80 from $70 and keeps a Buy rating on the shares after the TRANSCEND pivotal trial of setmelanotide in hypothalamic obesity met the primary endpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley
- Promising Phase 3 Results for Setmelanotide in Hypothalamic Obesity Drive Buy Rating
- BofA upgrades Rhythm Pharmaceuticals to Buy on ‘likely approvable’ data
- Rhythm Pharmaceuticals price target raised to $91 from $80 at Wells Fargo
- Rhythm Pharmaceuticals upgraded to Buy from Neutral at BofA